Massachusetts Financial Services Reduces $32M in Danaher Corporation ($DHR)
Massachusetts Financial Services trimmed its position in Danaher Corporation by 3.9%, as reported in its latest 13F filing.
Key Points
- Massachusetts Financial Services reduced its stake in Danaher Corporation by 3.9%, selling 167,287 shares, with a new total of 4,165,769 shares valued at approximately $817.3 million.
- Danaher's stock traded at $196.19 on Sunday, with a market cap of about $138.9 billion and a P/E ratio of 38.02.
- Insiders, including Charles Lamanna and Shane Sanders, purchased shares in May, and analysts like HSBC and Citigroup have maintained a 'buy' rating on the stock.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Massachusetts Financial Services has trimmed its position in Danaher Corporation (NYSE: DHR) by 3.9%, according to its latest 13F filing with the SEC. The fund sold 167,287 shares, bringing its total holdings to 4,165,769 shares, valued at approximately $817.3 million as of the end of the reporting period.
Massachusetts Financial Services vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
What Changed in Massachusetts Financial Services' Danaher Position
The fund cut its stake in Danaher by 3.9%, reducing its holdings from 4,333,056 shares to 4,165,769 shares. This adjustment reflects a decrease of 167,287 shares, with the remaining position valued at about $817.3 million.
Other Institutional Activity in Danaher Corporation
BlackRock, Inc. reduced its Danaher holdings by 396,733 shares, ending with 51,640,619 shares valued at roughly $9.79 billion, a slight decrease of 0.8%. Vanguard Capital Management LLC opened a new position with 41,127,810 shares, valued at approximately $7.80 billion. Meanwhile, State Street Corp increased its stake by 212,847 shares to a total of 27,894,181 shares, worth about $5.30 billion, marking a 0.8% increase. FMR LLC boosted its holdings by 3,027,600 shares, now holding 22,534,329 shares valued at $4.27 billion, a 15.5% increase. Conversely, JPMorgan Chase & Co cut its position by 4,667,877 shares, leaving it with 16,917,649 shares valued at $3.11 billion, a 21.6% decrease.
Danaher Corporation Stock Down 10.1%
Shares of NYSE:DHR traded near $196.19 on Sunday. Danaher Corporation has a market cap of approximately $138.9 billion, with a P/E ratio of 38.02 and a forward P/E of 21.30. The stock's beta is 0.834, indicating lower volatility compared to the market. It has a 52-week low of $160.93 and a high of $242.80, with a 50-day moving average of $178.75 and a 200-day moving average of $203.94. The company maintains a current ratio of 1.87, a quick ratio of 1.40, and a debt-to-equity ratio of 37.17.
$DHR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Danaher reported revenue of $24.78 billion, with a growth rate of 3.7%. The company's net margin stands at 14.89%, and it achieved a return on equity of 7.08%. Earnings per share are reported at $5.16. The next earnings report is expected on July 21, 2026.
Earnings drift grade
Outlook vs expectations on the last report — not price action.
-
Forward outlook
5 target cuts vs 1 raises.
-
EPS & revenue
EPS beat estimates by 5.3%. Revenue missed estimates by 1.8%.
-
Profit surprise
EBITDA missed by 22 percent. Operating income missed by 23 percent.
-
Pre-earnings setup
Bar was high, analysts already very bullish.
-
Analyst signal
1 target raise, 5 target cuts.
-
Earnings quality
Gross margin down 1.1 points. Positive free cash flow.
Earnings Call Summary
Danaher started 2026 solidly with adjusted earnings per share of $2.06, up 9.5 percent year over year, beating the consensus of $1.95. Revenue came in at $5.951 billion, slightly below the $6.057 billion expected, due mainly to a lighter respiratory season at Cepheid being down roughly 25 percent. However, strong bioprocessing momentum, with consumables up high single digits and equipment orders surging over 30 percent year over year for the first time in nearly two years, offset weakness. Diagnostics and Life Sciences showed pockets of improvement, with Beckman Coulter diagnostics growing mid single digits outside China and newer products like the Xpert GI panel gaining traction.
Guidance Management raised full year adjusted earnings per share to $8.35 to $8.55 from the prior range. Revenue guidance remains 3 percent to 6 percent growth for the full year, with lower respiratory sales of $1.6 billion to $1.7 billion offset by better core growth elsewhere. Second quarter expected to show low single digit core revenue growth with operating margins around 26.5 percent.
Severe negative reset. The report materially damaged the forward outlook and likely forces major downward revisions.
Dividend
Danaher Corporation offers an annual dividend rate of $1.60, yielding 0.82% with a payout ratio of 26.36%.
Insider Buying and Selling at Danaher Corporation
On May 15, 2026, several insiders, including Charles Lamanna, Shane Sanders, Linda Filler, and Alan Spoon, bought shares in Danaher Corporation. Each purchased 1,699 shares, with additional transactions by Sanders and Filler for 680 shares each. These transactions were not part of a pre-arranged trading plan.
Analysts Set New Price Targets
On June 11, 2026, Piper Sandler initiated coverage on Danaher with a hold rating and a $200 price target. HSBC maintained its buy rating with a $230 target on June 3, 2026. Citigroup reinstated a buy rating with a $230 target on May 27, 2026, but also downgraded the stock to hold with a $95 target on the same day. RBC Capital reinstated a buy rating with a $200 target on May 15, 2026. Overall, the consensus among 23 analysts is a strong buy, with a mean target price of $242.35.
About Danaher Corporation
Danaher Corporation, headquartered in Washington, DC, is a leading global provider of professional, medical, research, and industrial products and services. The company operates through three segments: Biotechnology, Life Sciences, and Diagnostics. It designs and manufactures a wide range of products, including technologies for therapeutic development, mass spectrometers, and clinical instruments. Led by CEO Rainer M. Blair, Danaher employs approximately 58,000 people worldwide.
Bottom Line
Massachusetts Financial Services' recent reduction in Danaher Corporation shares is part of broader institutional activity in the stock. Investors closely follow these filings to gauge institutional sentiment, though they reflect past positions as of the filing date. Danaher's strong market position and diverse product offerings continue to attract analyst attention and insider interest.
Get Danaher Corporation alerts
New 13F filings, insider trades, and analyst moves on $DHR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.